## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no full-text methods, figures, tables, or supplementary materials were provided
- **Shared manuscript claim summary** The authors propose that PFHxS, a short-chain PFAS, may contribute to hepatocellular carcinoma through engagement of the KEAP1-NRF2 axis. They integrate TCGA and single-cell transcriptomic analyses with molecular docking, molecular dynamics simulations, and in vitro assays in HepG2 cells to support a model in which PFHxS binds KEAP1, activates NRF2-NQO1 signaling, and increases MIF secretion.
- **Visible evidence base** Abstract text only; no numerical data, statistical details, docking scores, simulation parameters, or experimental protocols are visible
- **Missing materials affecting confidence** Full methods, all figures and tables, statistical analyses, docking and simulation parameters, cell line authentication details, dose-response data, and any exposure measurements

## Reviewer
- **Overall assessment** The abstract presents a plausible and potentially interesting hypothesis linking PFHxS exposure to KEAP1-NRF2 pathway activation in HCC. The integration of public transcriptomic data with computational and in vitro approaches is commendable in scope. However, the abstract alone provides insufficient quantitative evidence to evaluate the strength of the docking predictions, the magnitude and reproducibility of the in vitro effects, or the statistical robustness of the clinical associations. The authors appropriately acknowledge the lack of exposure data and the associative nature of the clinical findings, which is a strength. The central mechanistic claim, that PFHxS binds KEAP1 and activates NRF2-NQO1, is supported only by qualitative statements in the abstract and cannot be fully assessed without the underlying data.
- **Who would be interested in the results, and why** Researchers in environmental toxicology, PFAS health effects, liver cancer biology, and NRF2 signaling would find these results relevant. The work addresses a gap in understanding how short-chain PFAS may exert hepatocarcinogenic effects, which is of public health interest given the widespread detection of PFHxS in human populations.
- **Major strengths** The study integrates multiple complementary approaches, including clinical transcriptomics, single-cell analysis, computational modeling, and in vitro experiments. The authors are appropriately cautious in framing the clinical findings as associative rather than causal, given the absence of exposure data. The hypothesis is mechanistically coherent and testable.
- **Major Concerns**  
  - R1-M1  
  - R1-M2  
  - R1-M3  
  - R1-M4
- **Minor Comments**  
  - R1-m1  
  - R1-m2  
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria**  
  Originality: The hypothesis linking PFHxS to KEAP1-NRF2 activation is not entirely novel, as NRF2 pathway activation is a well-studied mechanism in chemical carcinogenesis, but the specific focus on PFHxS and the integration of single-cell data adds some originality. Scientific importance: The topic is of public health relevance, but the abstract does not establish a causal link, limiting the immediate importance of the findings. Interdisciplinary readership: The work bridges environmental health, computational biology, and cancer biology, which could attract a broad audience. Technical soundness: Cannot be fully evaluated from the abstract; the docking and simulation results are described only qualitatively, and the in vitro data lack quantitative detail. Readability for nonspecialists: The abstract is clearly written and accessible, with appropriate caveats about the associative nature of the clinical findings.
- **Recommendation posture** Supportive if technical concerns are resolved. The hypothesis is interesting and the multi-pronged approach is appropriate, but the abstract does not provide sufficient quantitative evidence to establish the central claims. Full data review is required.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical soundness  
- **Claim pointer** "Docking/dynamics suggested PFHxS can bind the KEAP1 Kelch domain near the NRF2-binding site."  
- **Evidence pointer** Abstract only; location not provided  
- **Concern** The abstract states that docking and molecular dynamics simulations "suggested" PFHxS binding to KEAP1, but no quantitative metrics are provided, such as binding free energies, docking scores, or simulation stability parameters. Without these data, the reliability of the computational prediction cannot be assessed.  
- **Why it matters** The computational binding prediction is a central pillar of the proposed mechanism. If the binding affinity is weak or the simulation is unstable, the entire hypothesis is weakened.  
- **Resolution test** Provide docking scores, binding free energy estimates, root-mean-square deviation plots, and comparison with known KEAP1 binders in the full manuscript.

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Technical soundness  
- **Claim pointer** "In HepG2 cells, PFHxS modestly increased viability/DNA-synthesis readouts and enhanced NRF2 nuclear localization, NQO1 protein abundance, and MIF secretion."  
- **Evidence pointer** Abstract only; location not provided  
- **Concern** The in vitro effects are described as "modest," but no effect sizes, dose-response relationships, or statistical significance values are reported. The abstract does not specify the concentrations of PFHxS used, the duration of exposure, or the number of independent replicates.  
- **Why it matters** The magnitude and reproducibility of the in vitro effects are critical to support the claim that PFHxS activates NRF2-NQO1 signaling. Without quantitative data, the biological relevance of the observed effects is unclear.  
- **Resolution test** Report dose-response curves, EC50 values, statistical tests with p-values, and effect sizes for all in vitro endpoints in the full manuscript.

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Scientific importance  
- **Claim pointer** "Higher NQO1, an NRF2-associated gene, was linked to adverse clinicopathologic features; NQO1-high tumor cells showed elevated NRF2-activity signatures and computationally inferred increased MIF signaling toward macrophages."  
- **Evidence pointer** Abstract only; location not provided  
- **Concern** The clinical association between NQO1 expression and adverse features is presented without hazard ratios, confidence intervals, or p-values. The single-cell analysis is described as "computationally inferred," which suggests the MIF signaling result is a prediction rather than a direct measurement.  
- **Why it matters** The clinical and single-cell findings are used to define a "PFHxS-relevant vulnerability axis," but the strength of these associations and the validity of the computational inference are not established.  
- **Resolution test** Provide survival analyses with hazard ratios and confidence intervals, and validate the MIF signaling inference with additional computational or experimental evidence.

- **Concern ID** R1-M4  
- **Severity** Major  
- **Blocking** No  
- **Axis** Interdisciplinary readership  
- **Claim pointer** "Pharmacologic NRF2 inhibition partially attenuated NRF2/NQO1 readouts and reduced MIF secretion."  
- **Evidence pointer** Abstract only; location not provided  
- **Concern** The abstract does not specify which pharmacologic inhibitor was used, at what concentration, or the degree of attenuation observed. The phrase "partially attenuated" is vague and does not allow the reader to judge the specificity or efficacy of the inhibition.  
- **Why it matters** The inhibitor experiment is intended to support the causal role of NRF2 in the observed effects. Without details on the inhibitor and the extent of attenuation, the strength of this evidence is unclear.  
- **Resolution test** Specify the inhibitor, its concentration, and report the percentage of attenuation for each endpoint in the full manuscript.

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Readability for nonspecialists  
- **Affected element** Abstract text  
- **Evidence pointer** Abstract; location not provided  
- **Issue** The abstract uses the term "PFHxS-relevant vulnerability axis" without defining what constitutes a "vulnerability axis" in this context.  
- **Required correction** Define the term or rephrase to clarify the intended meaning.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Technical soundness  
- **Affected element** Abstract text  
- **Evidence pointer** Abstract; location not provided  
- **Issue** The abstract states that "exposure information is unavailable" but does not clarify whether this refers to the TCGA cohort, the single-cell dataset, or both.  
- **Required correction** Specify which datasets lack exposure information.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Scientific importance  
- **Affected element** Abstract text  
- **Evidence pointer** Abstract; location not provided  
- **Issue** The abstract mentions "motivating exposure-characterized and genetic studies to establish causality" but does not suggest what specific genetic studies would be informative.  
- **Required correction** Briefly indicate the type of genetic studies envisioned, such as KEAP1 or NRF2 knockdown or knockout models.

## Risk / unsupported claims
- The claim that PFHxS binds KEAP1 is unsupported in the abstract because no quantitative docking or simulation data are provided.
- The claim that PFHxS activates NRF2-NQO1 signaling in HepG2 cells is unsupported because no effect sizes, concentrations, or statistical values are reported.
- The claim that NQO1-high tumor cells show increased MIF signaling toward macrophages is unsupported because the abstract indicates this was computationally inferred, and no validation is described.
- The clinical association between NQO1 and adverse features is not evaluable without hazard ratios, confidence intervals, or p-values.
- The overall hypothesis of a PFHxS-KEAP1-NRF2 axis in HCC is presented as plausible but is not established from the abstract alone.